Abbott Shows its Down With OCT in New Study

Abbott Laboratories has initiated a study to evaluate the long-term outcomes of patients who undergo stent implantation guided by optical coherence tomography (OCT) when compared to angiography. The Abbott Park, IL-based company said the ILUMIEN IV trial is the first large-scale randomized global study using Abbott's OCT imaging in patients with high-risk, complex coronary artery disease. Up to 3,650 patients will be evaluated and will be randomized to either OCT-guided or traditional angiography to guide placement of one or more Xience everolimus-eluting coronary stents. The first patient was enrolled by Franco Fabbiocchi, M.D., director of Invasive Cardiology Unit IV at IRCCS Centro Cardiologico Monzino in Milan, Italy. “There’s really nothing else out there like this study, certainly not with OCT,” Chuck Simonton M.D., CMO, of Abbott Vascular, told MD+DI. “There have been studies of a smaller size with Intravascular Ultrasound (IVUS). But no company with IVUS actually did a trial of this size with that technology, which can also see inside the vessel.” He noted that IVUS’s resolution was not as clear as OCT’s to view inside the vessel. If the results of ILUMIEN IV show that Abbott’s OCT technology is more effective, then it could be a game changer. However, as it stands now, the OCT technology is underutilized, Simonton said. Join us at the BIOMEDevice Boston Expo,  April 18–19, 2018. Use promo code "MDDI" for 20% off conference registration and free ex...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Cardiovascular Source Type: news